Who are Fludeoxyglucose F 18 (FDG)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tc 99m filtered sulfur colloid, Radium-223, Tc-99m Pentetate, 18F-rhPSMA-7.3, Technetium Tc99m Sestamibi, Sr-89.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludeoxyglucose-f-18-fdg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fludeoxyglucose F 18 (FDG) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludeoxyglucose F 18 (FDG) (Fludeoxyglucose F 18 (FDG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; PET imaging agent. Area: Oncology; Neurology; Cardiology.

marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase Oncology; Neurology; Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

Fludeoxyglucose F 18 (FDG) (Fludeoxyglucose F 18 (FDG)) — Teva Branded Pharmaceutical Products R&D, Inc.. Fludeoxyglucose F-18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling detection via positron emission tomography (PET) imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fludeoxyglucose F 18 (FDG) TARGET	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
Tc-99m Pentetate	Tc-99m Pentetate	NYU Langone Health	marketed	Radiopharmaceutical diagnostic agent
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; PET imaging agent class)

Clarity Pharmaceuticals Ltd · 1 drug in this class
Radiomedix, Inc. · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
UMC Utrecht · 1 drug in this class
University of Colorado, Denver · 1 drug in this class
University of Saskatchewan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludeoxyglucose F 18 (FDG) — Competitive Intelligence Brief. https://druglandscape.com/ci/fludeoxyglucose-f-18-fdg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab